It is somewhat serenditous in that I just completed the first draft of a tutorial that uses several genomic resources to look at the CYP2C9 gene variations and wafarin dosage, but a recent report in the NEJM looks at wafarin dosage from a combined clinical and pharmacogenetic data standpoint. As Daniel MacArthur at Genetic Future says,
“the real clinical benefits of widespread genetic screening will come first in pharmacogenomics – these results provide a neat demonstration of this process in action.”
And he also points to a nice tool the authors created for determining dosage based on CYP2C9 genotype and other indications. A taste of things to come.